T-VEC is administered via intralesional injection and functions by inducing direct tumor cell lysis and promoting an immunogenic response, which includes the upregulation of the granulocyte-macrophage colony-stimulating factor (GM-CSF) to recruit antigen-presenting cells and stimulate cytotoxic T lymphocytes [106]. Here, CSF2 is linked to neoplasm.